Clicky

Friday, November 20, 2026
All public companies · Official EDGAR

IVVDInvivyd, Inc.

Nasdaq · CIK 0001832038
Filer categoryNon-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Entity typeoperating
SIC2836 Biological Products, (No Diagnostic Substances)
FY end1231
XBRL facts254

Identity from submissions API

NameInvivyd, Inc.
CIK0001832038
TickersIVVD
ExchangesNasdaq
Entity typeoperating
CategoryNon-accelerated filer<br>Smaller reporting company<br>Emerging growth company
SIC2836 Biological Products, (No Diagnostic Substances)
EIN851403134
LEI—
Fiscal year end1231
State of incorporationDE DE
Phone(781) 819-0080
Website—
Investor website—
Owner org03 Life Sciences
Flags—
Description—
Insider transactions (issuer)1
Insider transactions (owner)0

Former names

  • Adagio Therapeutics, Inc. (2020-11-12T05:00:00.000Z → 2022-09-12T04:00:00.000Z)
Business address
205 CHURCH STREET
NEW HAVEN
CT
CT
Mailing address
205 CHURCH STREET
NEW HAVEN
CT
CT

EDGAR has no company-logo API. Website field is shown when the filer provided one.

Financialist coverage

SEC filings

452 filing rows loaded from submissions recent.

FiledFormDocumentItemsAccessionFile no.FilmActSizeXBRLiXBRL
2026-11-16 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001193125-26-463811 005-92804 261562671 34 10776
2026-11-16 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001012975-26-001059 005-92804 261560440 34 12085
2026-11-16 10-Q 10-Q 0001193125-26-462034 001-40703 261555373 34 11136512 1 1
2026-11-16 8-K 8-K 2.02,9.01 0001193125-26-462025 001-40703 261555365 34 1357632 1 1
2026-09-29 8-K 8-K 8.01,9.01 0001193125-26-406007 001-40703 261419146 34 12765705 1 1
2026-09-02 4 4 0001193125-26-380337 5544
2026-09-02 3 3 0001193125-26-380335 17514
2026-09-01 4 4 0001193125-26-378862 23723
2026-09-01 8-K 8-K 5.02,8.01,9.01 0001193125-26-377493 001-40703 261348505 34 1477829 1 1
2026-08-18 4 4 0001193125-26-355915 11331
2026-08-18 4 4 0001193125-26-355914 11312
2026-08-18 4 4 0001193125-26-355913 11321
2026-08-18 4 4 0001193125-26-355912 11971
2026-08-18 4 4 0001193125-26-355911 11392
2026-08-17 144 xsl144X01/primary_doc.xml 0001193125-26-354036 001-40703 261286699 33 4960
2026-08-17 144 xsl144X01/primary_doc.xml 0001193125-26-354034 001-40703 261286696 33 4939
2026-08-17 144 xsl144X01/primary_doc.xml 0001193125-26-354033 001-40703 261286695 33 4951
2026-08-17 144 xsl144X01/primary_doc.xml 0001193125-26-354032 001-40703 261286693 33 4910
2026-08-17 144 xsl144X01/primary_doc.xml 0001193125-26-354030 001-40703 261286686 33 4963
2026-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001193125-26-352642 005-92804 261283746 34 10700
2026-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000921895-26-002171 005-92804 261281638 34 25646
2026-08-13 10-Q 10-Q 0001193125-26-349215 001-40703 261273538 34 10951840 1 1
2026-08-13 8-K 8-K 2.02,9.01 0001193125-26-349193 001-40703 261273447 34 1354513 1 1
2026-08-04 4 4 0001193125-26-332844 5768
2026-08-04 3 3 0001193125-26-332833 22028
2026-07-28 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0002012383-26-002467 005-92804 261212503 34 10845
2026-07-24 8-K 8-K 3.01 0001193125-26-316066 001-40703 261201510 34 176151 1 1
2026-07-06 8-K 8-K 8.01,9.01 0001193125-26-295539 001-40703 261154241 34 1066795 1 1
2026-05-21 4 4 0001193125-26-234666 5447
2026-05-21 4 4 0001193125-26-234665 5451
2026-05-21 4 4 0001193125-26-234662 5558
2026-05-21 4 4 0001193125-26-234661 7983
2026-05-21 4 4 0001193125-26-234660 5467
2026-05-21 4 4 0001193125-26-234656 22313
2026-05-19 8-K 8-K 5.07 0001193125-26-230731 001-40703 26998589 34 193816 1 1
2026-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001346824-26-000155 005-92804 26988992 34 14829
2026-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000919574-26-003489 005-92804 26988201 34 12214
2026-05-14 S-8 S-8 0001193125-26-223973 333-295885 26978747 33 404708 1 1
2026-05-14 10-Q 10-Q 0001193125-26-222779 001-40703 26975821 34 8981829 1 1
2026-05-14 8-K 8-K 2.02,8.01,9.01 0001193125-26-222762 001-40703 26975810 34 8221340 1 1
2026-04-09 8-K 8-K 8.01,9.01 0001193125-26-148865 001-40703 26849800 34 5921048 1 1
2026-04-06 ARS ARS 0001193125-26-143853 001-40703 26841674 34 1068549
2026-04-06 DEFA14A DEFA14A 0001193125-26-143812 001-40703 26841539 34 1197528
2026-04-06 DEF 14A DEF 14A 0001193125-26-143783 001-40703 26841456 34 4863675 1 1
2026-03-05 10-K 10-K 0001193125-26-092547 001-40703 26724189 34 15131438 1 1
2026-03-05 8-K 8-K 2.02,8.01,9.01 0001193125-26-092528 001-40703 26724180 34 7410542 1 1
2026-02-18 4 4 0001193125-26-057828 11240
2026-02-18 4 4 0001193125-26-057822 11224
2026-02-18 4 4 0001193125-26-057819 11230
2026-02-18 4 4 0001193125-26-057815 11442
2026-02-18 4 4 0001193125-26-057814 11883
2026-02-17 144 xsl144X01/primary_doc.xml 0001193125-26-055377 001-40703 26644403 33 4982
2026-02-17 144 xsl144X01/primary_doc.xml 0001193125-26-055370 001-40703 26644377 33 5006
2026-02-17 144 xsl144X01/primary_doc.xml 0001193125-26-055365 001-40703 26644364 33 5003
2026-02-17 144 xsl144X01/primary_doc.xml 0001193125-26-055356 001-40703 26644354 33 4994
2026-02-17 144 xsl144X01/primary_doc.xml 0001193125-26-055348 001-40703 26644318 33 4955
2026-02-17 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001346824-26-000045 005-92804 26642283 34 15545
2026-02-17 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000902664-26-001128 005-92804 26641991 34 12428
2026-02-17 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000921895-26-000469 005-92804 26641721 34 25337
2026-02-13 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001012975-26-000135 005-92804 26632835 34 11842
2026-02-12 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001213900-26-015651 005-92804 26627407 34 29818
2026-01-30 4 4 0001193125-26-031858 5453
2026-01-30 4 4 0001193125-26-031856 5447
2026-01-30 4 4 0001193125-26-031840 5463
2026-01-30 4 4 0001193125-26-031822 5419
2026-01-30 4 4 0001193125-26-031819 5466
2026-01-08 8-K 8-K 2.02,8.01,9.01 0001193125-26-006997 001-40703 26517350 34 13776091 1 1
2025-12-29 SCHEDULE 13D/A xslSCHEDULE_13D_X01/primary_doc.xml 0001193125-25-335350 005-92804 251609322 34 8178
2025-12-23 EFFECT xslEFFECTX01/primary_doc.xml ,, 9999999995-25-003900 333-290685 251602316 33 1809
2025-12-23 144 xsl144X01/primary_doc.xml 0001950047-25-010678 001-40703 251600895 33 5697
2025-12-23 8-K 8-K 8.01,9.01 0001193125-25-329488 001-40703 251594686 34 319262 1 1
2025-12-19 CORRESP filename1.htm 0001193125-25-327185 6202
2025-12-19 S-3/A S-3/A 0001193125-25-327055 333-290685 251588454 33 310552 1 1
2025-11-25 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001193125-25-297003 005-92804 251520776 34 233346
2025-11-24 8-K 8-K 8.01,9.01 0001193125-25-291992 001-40703 251509558 34 323160 1 1
2025-11-20 4 4 0001193125-25-289825 4551
2025-11-19 8-K 8-K 1.01,8.01,9.01 0001193125-25-288347 001-40703 251500281 34 1381866 1 1
2025-11-19 SCHEDULE 13D/A xslSCHEDULE_13D_X01/primary_doc.xml 0001193125-25-288171 005-92804 251499720 34 135773
2025-11-19 424B5 424B5 0001193125-25-286661 333-267643 251496460 33 772945 1 1
2025-11-17 FWP FWP 0001193125-25-284712 333-267643 251491543 34 120235
2025-11-17 144 xsl144X01/primary_doc.xml 0001950047-25-008974 001-40703 251491500 33 4952
2025-11-17 424B5 424B5 0001193125-25-284616 333-267643 251491139 33 622125
2025-11-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000902664-25-004982 005-92804 251485550 34 12874
2025-11-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001274173-25-000285 005-92804 251483160 34 10739
2025-11-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001172661-25-004828 005-92804 251481398 34 11277
2025-11-12 SCHEDULE 13D/A xslSCHEDULE_13D_X01/primary_doc.xml 0001193125-25-277894 005-92804 251474036 34 17475
2025-11-07 SCHEDULE 13D/A xslSCHEDULE_13D_X01/primary_doc.xml 0001193125-25-272648 005-92804 251463808 34 31611
2025-11-06 10-Q 10-Q 0001193125-25-268076 001-40703 251456136 34 9924289 1 1
2025-11-06 8-K 8-K 2.02,8.01,9.01 0001193125-25-268057 001-40703 251456115 34 9438408 1 1
2025-10-30 8-K 8-K 8.01,9.01 0001193125-25-258526 001-40703 251435545 34 11387652 1 1
2025-10-22 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0000921895-25-002791 005-92804 251411165 34 38504
2025-10-14 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001213900-25-098418 005-92804 251389988 34 47457
2025-10-06 8-K 8-K 8.01,9.01 0001193125-25-230898 001-40703 251375591 34 326875 1 1
2025-10-02 S-3 S-3 0001193125-25-228321 333-290685 251369097 33 1229653 1 1
2025-09-24 4 4 0001193125-25-215634 5470
2025-09-24 3 3 0001193125-25-215619 21098
2025-09-24 8-K 8-K 5.02,7.01,8.01,9.01 0001193125-25-215541 001-40703 251339041 34 321311 1 1
2025-09-08 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001274173-25-000255 005-92804 251299381 34 9501
2025-08-29 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001415889-25-023305 005-92804 251281426 34 19666
2025-08-27 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0000902664-25-003863 005-92804 251265456 34 17942
2025-08-26 SCHEDULE 13D/A xslSCHEDULE_13D_X01/primary_doc.xml 0000902664-25-003854 005-92804 251257771 34 10294
2025-08-22 8-K 8-K 1.01,8.01,9.01 0000950170-25-110952 001-40703 251246314 34 1534334 1 1
2025-08-22 424B5 424B5 0001193125-25-185639 333-267643 251242132 33 758405 1 1
2025-08-20 FWP FWP 0001193125-25-184081 333-267643 251236893 34 83022
2025-08-20 424B5 424B5 0001193125-25-184075 333-267643 251236853 33 611923
2025-08-19 4 4 0000950170-25-110346 30695
2025-08-19 4 4 0000950170-25-110344 31808
2025-08-19 4 4 0000950170-25-110343 31692
2025-08-19 4 4 0000950170-25-110341 31834
2025-08-19 4 4 0000950170-25-110339 31182
2025-08-18 144 xsl144X01/primary_doc.xml 0001123292-25-000376 001-40703 251229252 33 19262
2025-08-18 144 xsl144X01/primary_doc.xml 0001123292-25-000374 001-40703 251229251 33 20995
2025-08-18 144 xsl144X01/primary_doc.xml 0001123292-25-000372 001-40703 251229247 33 19275
2025-08-18 144 xsl144X01/primary_doc.xml 0001123292-25-000370 001-40703 251229244 33 19102
2025-08-18 144 xsl144X01/primary_doc.xml 0001123292-25-000368 001-40703 251229236 33 19380
2025-08-14 10-Q 10-Q 0000950170-25-109029 001-40703 251220667 34 9473381 1 1
2025-08-14 8-K 8-K 2.02,8.01,9.01 0001193125-25-180890 001-40703 251220584 34 10174699 1 1
2025-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001641172-25-023725 005-92804 251214432 34 11824
2025-07-02 8-K 8-K 8.01,9.01 0000950170-25-092528 001-40703 251098322 34 342275 1 1
2025-06-26 8-K 8-K 8.01,9.01 0000950170-25-090172 001-40703 251075049 34 352220 1 1
2025-05-22 4 4 0000950170-25-076343 5473
2025-05-22 4 4 0000950170-25-076337 5415
2025-05-22 4 4 0000950170-25-076332 5406
2025-05-22 4 4 0000950170-25-076323 7834
2025-05-22 4 4 0000950170-25-076316 5393
2025-05-22 4 4 0000950170-25-076305 5359
2025-05-20 8-K 8-K 5.07 0000950170-25-075199 001-40703 25969011 34 196193 1 1
2025-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001172661-25-001965 005-92804 25948985 34 11381
2025-05-15 10-Q 10-Q 0000950170-25-071974 001-40703 25948681 34 8073162 1 1
2025-05-15 8-K 8-K 2.02,8.01,9.01 0001193125-25-120261 001-40703 25948646 34 15276187 1 1
2025-05-12 8-K 8-K 8.01,9.01 0000950170-25-068543 001-40703 25932552 34 331325 1 1
2025-04-25 8-K 8-K 3.01 0000950170-25-058705 001-40703 25873935 34 180496 1 1
2025-04-21 8-K 8-K 1.01,2.03,7.01,9.01 0000950170-25-056005 001-40703 25851291 34 1289004 1 1
2025-04-07 ARS ARS 0000950170-25-051619 001-40703 25818482 34 1023397
2025-04-07 DEFA14A DEFA14A 0000950170-25-051610 001-40703 25818411 34 1608413
2025-04-07 DEF 14A DEF 14A 0000950170-25-051587 001-40703 25818243 34 3807396 1 1
2025-03-26 4 4 0000950170-25-045465 5497
2025-03-26 3 3 0000950170-25-045455 17298
2025-03-26 8-K 8-K 5.02,7.01,9.01 0000950170-25-045302 001-40703 25773696 34 327230 1 1
2025-03-20 10-K 10-K 0000950170-25-042332 001-40703 25754572 34 12962155 1 1
2025-03-20 8-K 8-K 2.02,9.01 0000950170-25-042331 001-40703 25754555 34 541350 1 1
2025-03-05 8-K 8-K 8.01,9.01 0000950170-25-033068 001-40703 25708808 34 335067 1 1
2025-02-24 8-K 8-K 8.01,9.01 0000950170-25-025227 001-40703 25654180 34 341971 1 1
2025-02-19 4 4 0000950170-25-023245 8102
2025-02-19 4 4 0000950170-25-023241 8150
2025-02-19 4 4 0000950170-25-023239 8164
2025-02-19 4 4 0000950170-25-023238 8131
2025-02-19 4 4 0000950170-25-023232 8147
2025-02-12 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000315066-25-000768 005-92804 25612389 34 11459
2025-02-03 8-K 8-K 2.02,8.01,9.01 0000950170-25-012018 001-40703 25580580 34 1723528 1 1
2025-01-27 8-K 8-K 8.01,9.01 0000950170-25-008995 001-40703 25555755 34 338577 1 1
2025-01-10 8-K 8-K 8.01,9.01 0000950170-25-003781 001-40703 25520370 34 335507 1 1
2024-12-31 4 4 0000950170-24-141701 18802
2024-12-27 8-K 8-K 3.01 0000950170-24-140800 001-40703 241585863 34 177169 1 1
2024-12-26 4 4 0000950170-24-140613 20890
2024-12-20 144 xsl144X01/primary_doc.xml 0001950047-24-010012 001-40703 241568580 33 11131
2024-12-19 4 4 0000950170-24-138597 18800
2024-12-16 4 4 0000950170-24-136858 16715
2024-12-12 SC 13D/A SC 13D/A 0001193125-24-277124 005-92804 241545416 34 198107
2024-12-11 4 4 0000950170-24-135509 18804
2024-12-09 144 xsl144X01/primary_doc.xml 0001950047-24-009555 001-40703 241535434 33 5085
2024-12-02 8-K 8-K 5.02 0000950170-24-132158 001-40703 241518615 34 167384 1 1
2024-11-14 SC 13G/A SC 13G/A 0001193125-24-258666 005-92804 241463169 34 66409
2024-11-14 SC 13G/A deeptrack-ivvd093024a1.htm 0001172661-24-004731 005-92804 241457687 34 103260
2024-11-14 10-Q 10-Q 0000950170-24-126735 001-40703 241457177 34 7908798 1 1
2024-11-14 8-K 8-K 2.02,8.01,9.01 0001193125-24-257993 001-40703 241457170 34 7250824 1 1
2024-11-12 SC 13G/A filing.txt 0000315066-24-002844 005-92804 241444873 34 8099
2024-11-08 SC 13G/A SC 13G/A 0001104659-24-115886 005-92804 241440869 34 246499
2024-10-29 8-K 8-K 2.02,8.01,9.01 0000950170-24-117934 001-40703 241402678 34 362190 1 1
2024-09-23 8-K 8-K 8.01,9.01 0000950170-24-108624 001-40703 241314615 34 10239665 1 1
2024-09-06 8-K 8-K 8.01,9.01 0001193125-24-214779 001-40703 241283076 34 6921038 1 1
2024-09-04 8-K 8-K 8.01,9.01 0000950170-24-103100 001-40703 241275850 34 228742 1 1
2024-09-03 8-K 8-K 8.01,9.01 0000950170-24-102552 001-40703 241271886 34 237333 1 1
2024-08-27 8-K 8-K 8.01,9.01 0001193125-24-207466 001-40703 241243447 34 6539433 1 1
2024-08-14 10-Q 10-Q 0000950170-24-096674 001-40703 241204325 34 8100852 1 1
2024-08-14 8-K 8-K 2.02,8.01,9.01 0001193125-24-200256 001-40703 241204316 34 10837893 1 1
2024-06-14 8-K 8-K 8.01,9.01 0000950170-24-073322 001-40703 241043131 34 319130 1 1
2024-06-06 4 4 0000950170-24-069965 5672
2024-06-06 3 3 0000950170-24-069959 13115
2024-05-31 4 4 0000950170-24-067438 14354
2024-05-31 8-K 8-K 5.02,8.01,9.01 0001193125-24-151007 001-40703 241007668 34 228128 1 1
2024-05-29 144 xsl144X01/primary_doc.xml 0001963745-24-000026 001-40703 24999839 33 4649
2024-05-23 4 4 0000950170-24-064152 5481
2024-05-23 4 4 0000950170-24-064146 5374
2024-05-23 4 4 0000950170-24-064138 5545
2024-05-23 4 4 0000950170-24-064126 5423
2024-05-23 4 4 0000950170-24-064113 7845
2024-05-23 4 4 0000950170-24-064071 5401
2024-05-23 3 3 0000950170-24-064026 14384
2024-05-23 4 4 0000950170-24-064007 5511
2024-05-23 3 3 0000950170-24-064003 14346
2024-05-22 8-K 8-K 5.07,7.01,9.01 0000950170-24-063279 001-40703 24971630 34 346485 1 1
2024-05-16 144 xsl144X01/primary_doc.xml 0001950047-24-003783 001-40703 24955657 33 4818
2024-05-09 S-8 S-8 0000950170-24-057117 333-279268 24931289 33 201177
2024-05-09 10-Q 10-Q 0000950170-24-057017 001-40703 24931034 34 6217875 1 1
2024-05-09 8-K 8-K 2.02,8.01,9.01 0001193125-24-135260 001-40703 24930560 34 11255779 1 1
2024-05-07 8-K 8-K 8.01,9.01 0001193125-24-132585 001-40703 24919642 34 200137 1 1
2024-04-19 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2024-04-19 16:00:00 9999999995-24-001044 333-276986 24859415 33 1857
2024-04-18 ARS ARS 0000950170-24-045570 001-40703 24854482 34 956791
2024-04-18 CORRESP filename1.htm 0000950170-24-045558 11739
2024-04-18 DEF 14A DEF 14A 0000950170-24-045549 001-40703 24854354 34 2134232
2024-04-12 8-K 8-K 5.02,7.01,9.01 0001193125-24-093929 001-40703 24839995 34 204621 1 1
2024-04-04 8-K 8-K 8.01,9.01 0001193125-24-087408 001-40703 24824089 34 4285401 1 1
2024-03-28 10-K 10-K 0000950170-24-037610 001-40703 24793481 34 12096930 1 1
2024-03-28 8-K 8-K 2.02,9.01 0001193125-24-079597 001-40703 24793458 34 278512 1 1
2024-03-25 8-K 8-K 2.02,8.01,9.01 0001193125-24-075582 001-40703 24776704 34 11538284 1 1
2024-02-23 UPLOAD filename1.pdf 0000000000-24-002075 333-276986 40345
2024-02-14 SC 13G SC 13G 0001193125-24-036575 005-92804 24640483 34 79556
2024-02-12 SC 13G deeptrack-ivvd020224.htm 0001172661-24-000706 005-92804 24619758 34 103112
2024-02-09 S-3 S-3 0001193125-24-030154 333-276986 24615737 33 375601
2024-02-09 8-K 8-K 5.02,8.01,9.01 0000950170-24-013243 001-40703 24614638 34 8624012 1 1
2024-02-09 SC 13G/A filing.txt 0000315066-24-001257 005-92804 24611767 34 8126
2024-01-26 4 4 0000950170-24-007981 5495
2024-01-26 3 3 0000950170-24-007972 18463
2024-01-22 4 4 0000950170-24-006070 4544
2024-01-22 SC 13D/A SC 13D/A 0001193125-24-012170 005-92804 24549020 34 33892
2024-01-19 144 xsl144X01/primary_doc.xml 0001950047-24-000381 001-40703 24545912 33 5009
2024-01-08 8-K 8-K 8.01,9.01 0001193125-24-003875 001-40703 24518318 34 9180049 1 1
2024-01-03 8-K 8-K 8.01,9.01 0001193125-24-001013 001-40703 24504335 34 186384 1 1
2023-12-22 8-K 8-K 1.01,9.01 0001193125-23-302195 001-40703 231510549 34 420730 1 1
2023-12-22 424B5 424B5 0001193125-23-302190 333-267643 231510533 33 525436
2023-12-20 4 4 0000950170-23-071919 5490
2023-12-20 4 4 0000950170-23-071918 5492
2023-12-20 4 4 0000950170-23-071915 5495
2023-12-20 4 4 0000950170-23-071914 5501
2023-12-20 4 4 0000950170-23-071909 5468
2023-12-20 4 4 0000950170-23-071907 5532
2023-12-20 4 4 0000950170-23-071905 5517
2023-12-18 8-K FORM 8-K 8.01,9.01 0001193125-23-297099 001-40703 231492237 34 183539 1 1
2023-11-20 4 4 0000950170-23-065108 5553
2023-11-09 8-K 8-K 2.02,8.01,9.01 0001193125-23-274506 001-40703 231392498 34 5424400 1 1
2023-11-09 10-Q 10-Q 0000950170-23-062043 001-40703 231392478 34 9472900 1 1
2023-09-11 SC 13G/A filing.txt 0000315066-23-002573 005-92804 231246761 34 8018
2023-09-11 8-K 8-K 8.01,9.01 0001193125-23-231961 001-40703 231246677 34 10337462 1 1
2023-09-05 4 4 0000950170-23-046430 5612
2023-09-05 3 3 0000950170-23-046412 14636
2023-09-05 8-K 8-K 5.02,7.01,9.01 0001193125-23-228074 001-40703 231234116 34 350531 1 1
2023-08-10 10-Q 10-Q 0000950170-23-041352 001-40703 231159743 34 9503514 1 1
2023-08-10 8-K 8-K 2.02,9.01 0001193125-23-209020 001-40703 231159209 34 248758 1 1
2023-07-27 4 4 0000950170-23-035191 5430
2023-07-27 3 3 0000950170-23-035177 8583
2023-07-27 8-K 8-K 5.02,7.01,9.01 0001193125-23-196086 001-40703 231118434 34 174631 1 1
2023-06-29 8-K 8-K 8.01,9.01 0001193125-23-177996 001-40703 231054279 34 9911207 1 1
2023-05-25 4 FORM 4 SUBMISSION 0000899243-23-013935 10707
2023-05-25 4 FORM 4 SUBMISSION 0000899243-23-013920 10648
2023-05-25 4 FORM 4 SUBMISSION 0000899243-23-013918 10631
2023-05-25 4 FORM 4 SUBMISSION 0000899243-23-013917 5549
2023-05-25 4 FORM 4 SUBMISSION 0000899243-23-013916 5534
2023-05-25 4 FORM 4 SUBMISSION 0000899243-23-013913 5569
2023-05-25 4 FORM 4 SUBMISSION 0000899243-23-013912 7916
2023-05-25 8-K 8-K 5.03,5.07,9.01 0001193125-23-154233 001-40703 23960922 34 185939 1 1
2023-05-11 10-Q 10-Q 0000950170-23-021235 001-40703 23911122 34 8626357 1 1
2023-05-11 8-K 8-K 2.02,9.01 0001193125-23-142010 001-40703 23911017 34 235679 1 1
2023-05-02 8-K 8-K 5.02,8.01,9.01 0001193125-23-131287 001-40703 23876630 34 8774555 1 1
2023-04-12 4 FORM 4 SUBMISSION 0000899243-23-011197 5826
2023-04-12 3 FORM 3 SUBMISSION 0000899243-23-011195 7703
2023-04-10 ARS ARS 0000950170-23-012300 001-40703 23811359 34 2533846
2023-04-10 DEFA14A DEFA14A 0001193125-23-096532 001-40703 23811251 34 120329
2023-04-10 DEF 14A DEF 14A 0001193125-23-096524 001-40703 23811223 34 734585
2023-03-31 PRE 14A PRE 14A 0001193125-23-088183 001-40703 23788465 34 491559
2023-03-28 4 FORM 4 SUBMISSION 0000899243-23-009798 5808
2023-03-28 3 FORM 3 SUBMISSION 0000899243-23-009795 7672
2023-03-23 10-K 10-K 0000950170-23-009516 001-40703 23756632 34 14862400 1 1
2023-03-23 8-K 8-K 2.02,9.01 0001193125-23-077876 001-40703 23756337 34 238764 1 1
2023-03-06 8-K 8-K 8.01,9.01 0001193125-23-060699 001-40703 23707581 34 6911656 1 1
2023-02-09 SC 13G/A filing.txt 0000315066-23-001757 005-92804 23603099 34 8218
2023-01-09 8-K FORM 8-K 8.01,9.01 0001193125-23-004133 001-40703 23516537 34 5952398 1 1
2022-12-16 4 FORM 4 SUBMISSION 0000899243-22-038853 10283
2022-12-16 4 FORM 4 SUBMISSION 0000899243-22-038851 5582
2022-12-16 4 FORM 4 SUBMISSION 0000899243-22-038849 5609
2022-12-16 4 FORM 4 SUBMISSION 0000899243-22-038845 5768
2022-12-16 3 FORM 3 SUBMISSION 0000899243-22-038844 7688
2022-12-16 4 FORM 4 SUBMISSION 0000899243-22-038843 8516
2022-12-06 4 FORM 4 SUBMISSION 0000899243-22-037804 5607
2022-12-06 3 FORM 3 SUBMISSION 0000899243-22-037803 11056
2022-12-06 8-K FORM 8-K 5.02,8.01,9.01 0001193125-22-299428 001-40703 221448106 34 358301 1 1
2022-11-29 D xslFormDX01/primary_doc.xml 06b 0001567619-22-021016 021-466075 221433610 33 15059
2022-11-17 8-K 8-K 1.01,3.02,8.01,9.01 0001193125-22-287208 001-40703 221396822 34 190668 1 1
2022-11-10 10-Q 10-Q 0000950170-22-024516 001-40703 221377692 34 13131594 1 1
2022-11-10 8-K 8-K 2.02,9.01 0001193125-22-282613 001-40703 221377325 34 244686 1 1
2022-11-04 4 FORM 4 SUBMISSION 0000899243-22-035198 5496
2022-10-24 4 FORM 4 SUBMISSION 0000899243-22-034029 5630
2022-10-24 3 FORM 3 SUBMISSION 0000899243-22-034028 7600
2022-10-24 8-K 8-K 5.02,7.01,9.01 0001193125-22-267606 001-40703 221326312 34 174541 1 1
2022-10-13 3 FORM 3 SUBMISSION 0000899243-22-033561 7640
2022-10-13 8-K 8-K 5.02,7.01,9.01 0001193125-22-262167 001-40703 221309240 34 331175 1 1
2022-10-05 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2022-10-05 16:00:00 9999999995-22-002946 333-267643 221297028 33 1809
2022-10-03 CORRESP filename1.htm 0001193125-22-256380 6344
2022-09-30 UPLOAD filename1.pdf 0000000000-22-010798 40251
2022-09-28 S-3 S-3 0001193125-22-253372 333-267643 221276888 33 818202
2022-09-13 8-K 8-K 5.03,9.01 0001193125-22-243285 001-40703 221239737 34 307146 1 1
2022-09-12 8-K 8-K 8.01,9.01 0001193125-22-242433 001-40703 221237388 34 13428364 1 1
2022-09-01 4 FORM 4 SUBMISSION 0000899243-22-030183 4977
2022-08-19 SC 13D/A ADAGIO THERAPEUTICS, INC. 0000902664-22-004064 005-92804 221181631 34 57234
2022-08-19 4 FORM 4 SUBMISSION 0000899243-22-029295 11409
2022-08-15 10-Q 10-Q 0000950170-22-017242 001-40703 221162454 34 9912327 1 1
2022-08-15 8-K 8-K 2.02,9.01 0001193125-22-220559 001-40703 221162314 34 252515 1 1
2022-07-06 4 FORM 4 SUBMISSION 0000899243-22-025328 9484
2022-07-05 8-K 8-K 5.02,8.01,9.01 0001193125-22-187977 001-40703 221065726 34 382740 1 1
2022-07-05 SC 13D/A SC 13D/A 0001193125-22-187564 005-92804 221063233 34 105647
2022-06-30 8-K 8-K 5.02 0001193125-22-186218 001-40703 221058397 34 146862 1 1
2022-06-24 SC 13D/A SC 13D/A 0001193125-22-181642 005-92804 221040882 34 98831
2022-06-24 SC 13D/A SCHEDULE 13D (AMENDMENT NO. 2) 0000914121-22-004040 005-92804 221040868 34 101303
2022-06-24 4 FORM 4 SUBMISSION 0000899243-22-024047 10171
2022-06-24 SC 13D/A SC 13D/A 0001193125-22-181609 005-92804 221040769 34 30082
2022-06-24 SC 13D/A SC 13D/A 0001193125-22-181596 005-92804 221040708 34 200974
2022-06-24 4 FORM 4 SUBMISSION 0000899243-22-024027 5560
2022-06-24 4 FORM 4 SUBMISSION 0000899243-22-024021 12404
2022-06-24 3 FORM 3 SUBMISSION 0000899243-22-024018 7601
2022-06-24 4 FORM 4 SUBMISSION 0000899243-22-024015 5438
2022-06-24 4 FORM 4 SUBMISSION 0000899243-22-024012 5427
2022-06-24 4 FORM 4 SUBMISSION 0000899243-22-023996 5407
2022-06-24 4 FORM 4 SUBMISSION 0000899243-22-023984 5446
2022-06-24 4 FORM 4 SUBMISSION 0000899243-22-023969 5506
2022-06-24 SC 13D/A ADAGIO THERAPEUTICS, INC. 0000902664-22-003399 005-92804 221040284 34 51597
2022-06-22 8-K 8-K 5.07 0001193125-22-178882 001-40703 221032915 34 164734 1 1
2022-06-21 DEFA14C DEFA14C 0001193125-22-177782 001-40703 221029104 34 9635
2022-06-21 8-K 8-K 5.02 0001193125-22-177777 001-40703 221029080 34 147837 1 1
2022-06-06 DFAN14A DFAN14A 0001193125-22-167561 001-40703 22996589 34 620379
2022-06-02 DEFC14C DEFC14C 0001193125-22-166247 001-40703 22991131 34 426302
2022-05-31 CORRESP filename1.htm 0001193125-22-164093 22209
2022-05-31 PRER14C PRER14C 0001193125-22-164089 001-40703 22984514 34 398281
2022-05-27 UPLOAD filename1.pdf 0000000000-22-005843 44395
2022-05-19 DEFA14C DEFA14C 0001193125-22-155177 001-40703 22944240 34 11028
2022-05-19 8-K 8-K 8.01 0001193125-22-155156 001-40703 22944122 34 149838 1 1
2022-05-19 PREC14C PREC14C 0001193125-22-155139 001-40703 22944030 34 397450
2022-05-13 S-8 S-8 0001193125-22-149581 333-264920 22920827 33 82802
2022-05-13 10-Q 10-Q 0000950170-22-009799 001-40703 22920298 34 8546031 1 1
2022-05-13 8-K 8-K 2.02,9.01 0001193125-22-149345 001-40703 22920206 34 233606 1 1
2022-04-29 10-K/A 10-K/A 0001193125-22-134035 001-40703 22876502 34 773655 1 1
2022-04-29 DEFC14A DEFC14A 0001193125-22-133527 001-40703 22875068 34 953488
2022-04-27 PRRN14A PRRN14A 0001193125-22-122799 001-40703 22858410 34 899946
2022-04-26 SC 13D/A ADAGIO THERAPEUTICS, INC. 0000902664-22-002675 005-92804 22852581 34 51929
2022-04-26 PREC14A PREC14A 0001193125-22-118162 001-40703 22851910 34 1229155
2022-04-26 SC 13D/A SCHEDULE 13D (AMENDMENT NO. 1) 0000914121-22-003216 005-92804 22851589 34 117316
2022-04-26 SC 13D/A SC 13D/A 0001193125-22-118343 005-92804 22851565 34 209439
2022-04-26 SC 13D/A SC 13D/A 0001193125-22-118329 005-92804 22851547 34 104772
2022-04-26 SC 13D/A SC 13D/A 0001193125-22-118250 005-92804 22851367 34 38807
2022-04-25 PRRN14A PRRN14A 0001193125-22-117915 001-40703 22850836 34 956437
2022-04-18 UPLOAD filename1.pdf 0000000000-22-004153 49015
2022-04-11 PREC14A PREC14A 0001193125-22-100921 001-40703 22818462 34 822366
2022-04-07 SC 13D SCHEDULE 13D 0000914121-22-002824 005-92804 22811627 34 145082
2022-04-06 3/A FORM 3/A 0001567619-22-008202 14894
2022-04-01 3 xslF345X02/ownership.xml 0000902664-22-002394 7972
2022-04-01 4 FORM 4 SUBMISSION 0000899243-22-013098 6849
2022-04-01 SC 13D ADAGIO THERAPEUTICS, INC. 0000902664-22-002385 005-92804 22795651 34 88659
2022-03-31 10-K 10-K 0000950170-22-005112 001-40703 22789236 34 18458001 1 1
2022-03-30 3 FORM 3 0001567619-22-007732 6627
2022-03-30 3 FORM 3 0001567619-22-007730 6643
2022-03-30 4 FORM 4 SUBMISSION 0000899243-22-012866 6454
2022-03-30 4 FORM 4 SUBMISSION 0000899243-22-012864 11838
2022-03-30 4 FORM 4 SUBMISSION 0000899243-22-012830 14294
2022-03-30 3 FORM 3 SUBMISSION 0000899243-22-012829 30843
2022-03-30 SC 13D SC 13D 0001193125-22-089834 005-92804 22786749 34 58991
2022-03-30 8-K 8-K 2.02,9.01 0001193125-22-088649 001-40703 22783171 34 255591 1 1
2022-03-30 SC 13D/A SC 13D/A 0001193125-22-088640 005-92804 22783159 34 213857
2022-03-30 SC 13D/A SC 13D/A 0001193125-22-088618 005-92804 22783147 34 111571
2022-03-21 8-K 8-K 5.02,8.01,9.01 0001193125-22-080001 001-40703 22754171 34 326227 1 1
2022-03-21 8-K/A 8-K/A 5.02,9.01 0001193125-22-079997 001-40703 22754170 34 333861 1 1
2022-03-01 8-K 8-K 5.02 0001193125-22-061608 001-40703 22699498 34 148741 1 1
2022-02-23 8-K 8-K 5.02,8.01,9.01 0001193125-22-050174 001-40703 22664890 34 177250 1 1
2022-02-22 8-K 8-K 8.01,9.01 0001193125-22-047719 001-40703 22655047 34 205547 1 1
2022-02-18 8-K 8-K 5.02 0001193125-22-046765 001-40703 22654027 34 148451 1 1
2022-02-14 SC 13G SC 13G 0001193125-22-040725 005-92804 22628119 34 199134
2022-02-11 SC 13G/A SC 13G/A 0000905718-22-000207 005-92804 22620508 34 47143
2022-02-09 SC 13G/A filing.txt 0000315066-22-000818 005-92804 22604148 34 8838
2022-02-01 4 FORM 4 SUBMISSION 0001209191-22-006030 5466
2022-02-01 4 FORM 4 SUBMISSION 0001209191-22-006027 5454
2022-02-01 4 FORM 4 SUBMISSION 0001209191-22-006024 5455
2022-02-01 4 FORM 4 SUBMISSION 0001209191-22-006022 5490
2022-02-01 4 FORM 4 SUBMISSION 0001209191-22-006020 5463
2022-02-01 4 FORM 4 SUBMISSION 0001209191-22-006015 5454
2022-02-01 4 FORM 4 SUBMISSION 0001209191-22-006011 5463
2022-01-13 8-K 8-K 7.01,8.01,9.01 0001193125-22-008197 001-40703 22527905 34 184462 1 1
2021-12-14 8-K 8-K 7.01,9.01 0001193125-21-356251 001-40703 211489794 34 173692 1 1
2021-11-29 8-K 8-K 7.01,9.01 0001193125-21-341832 001-40703 211452974 34 183359 1 1
2021-11-23 4 FORM 4 SUBMISSION 0001209191-21-066591 5427
2021-11-23 4 FORM 4 SUBMISSION 0001209191-21-066581 5310
2021-11-22 3 FORM 3 SUBMISSION 0001209191-21-066196 6740
2021-11-22 3 FORM 3 SUBMISSION 0001209191-21-066195 6962
2021-11-22 8-K 8-K 5.02,7.01,9.01 0001193125-21-336946 001-40703 211433393 34 186475 1 1
2021-11-16 8-K 8-K 7.01 0001193125-21-331387 001-40703 211417424 34 148725 1 1
2021-11-15 10-Q 10-Q 0000950170-21-004586 001-40703 211410476 34 9614487 1 1
2021-11-15 8-K 8-K 2.02,9.01 0001193125-21-328992 001-40703 211406492 34 286332 1 1
2021-11-03 3/A FORM 3/A SUBMISSION 0001209191-21-062724 4630
2021-11-02 4 FORM 4 SUBMISSION 0001209191-21-062491 5466
2021-11-02 3 FORM 3 SUBMISSION 0001209191-21-062483 8559
2021-10-19 8-K 8-K 8.01,9.01 0001193125-21-301964 001-40703 211330937 34 173544 1 1
2021-10-05 SC 13G INITIAL FILING 0000905718-21-001274 005-92804 211306748 34 46868
2021-09-29 8-K 8-K 8.01,9.01 0001193125-21-286813 001-40703 211292233 34 184580 1 1
2021-09-20 10-Q 10-Q 0000950170-21-001832 001-40703 211263503 34 8838294 1 1
2021-09-20 8-K 8-K 2.02,9.01 0001193125-21-277284 001-40703 211263303 34 108804
2021-09-10 SC 13G filing.txt 0000315066-21-001719 005-92804 211246034 34 8864
2021-09-10 8-K 8-K 8.01,9.01 0001193125-21-269490 001-40703 211245879 34 28205
2021-08-23 S-8 S-8 0001193125-21-254034 333-259008 211197411 33 86963
2021-08-20 SC 13D SC 13D 0001193125-21-252785 005-92804 211194154 34 121269
2021-08-20 SC 13D SC 13D 0001193125-21-252773 005-92804 211194086 34 246019
2021-08-13 SEC STAFF LETTER filename1.pdf 9999999997-21-004514 271704
2021-08-12 4 FORM 4 SUBMISSION 0001209191-21-051299 14642
2021-08-12 4 FORM 4 SUBMISSION 0001209191-21-051298 19228

Latest XBRL company facts

One latest value per concept from companyfacts (254 concepts). Full history stays in the JSON.

TaxonomyTagLabelUnitValueStartEndFYFPFormFiledAccn
dei EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding shares 295.63M 2026-10-29 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
dei EntityPublicFloat Entity Public Float USD 50.90M 2025-06-30 2025 FY 10-K 2026-03-05 0001193125-26-092547
ffd NetFeeAmt NetFeeAmt USD 4,939.67 2026-05-13 S-8 2026-05-14 0001193125-26-223973
ffd TtlFeeAmt TtlFeeAmt USD 4,939.67 2026-05-13 S-8 2026-05-14 0001193125-26-223973
ffd TtlOfferingAmt TtlOfferingAmt USD 35.77M 2026-05-13 S-8 2026-05-14 0001193125-26-223973
ffd TtlOffsetAmt TtlOffsetAmt USD 0 2026-05-13 S-8 2026-05-14 0001193125-26-223973
us-gaap AccountsPayableCurrent Accounts Payable, Current USD 6.37M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap AccountsReceivableGrossCurrent Accounts Receivable, before Allowance for Credit Loss, Current USD 13.90M 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092547
us-gaap AccountsReceivableNetCurrent Accounts Receivable, after Allowance for Credit Loss, Current USD 12.19M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap AccretionAmortizationOfDiscountsAndPremiumsInvestments Accretion (Amortization) of Discounts and Premiums, Investments USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-20 0000950170-25-042332
us-gaap AccruedEmployeeBenefitsCurrent Accrued Employee Benefits, Current USD 6.10M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap AccruedLiabilitiesCurrent Accrued Liabilities, Current USD 18.71M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap AccruedLiabilitiesCurrentAndNoncurrent Accrued Liabilities USD 18.71M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap AccruedProfessionalFeesCurrentAndNoncurrent Accrued Professional Fees USD 3.23M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap AccumulatedOtherComprehensiveIncomeLossNetOfTax Accumulated Other Comprehensive Income (Loss), Net of Tax USD -35,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap AdditionalPaidInCapitalCommonStock Additional Paid in Capital, Common Stock USD 1.22B 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap AdjustmentForAmortization Amortization USD 280.19M 2022-01-01 2022-12-31 2023 FY 10-K 2024-03-28 0000950170-24-037610
us-gaap AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD 2.74M 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap AllocatedShareBasedCompensationExpense Share-based Payment Arrangement, Expense USD 8.33M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables Allowance for Doubtful Accounts, Premiums and Other Receivables USD 49,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap AllowanceForDoubtfulAccountsReceivableCurrent Accounts Receivable, Allowance for Credit Loss, Current USD 100,000 2026-06-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount shares 48.77M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap Assets Assets USD 183.91M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap AssetsCurrent Assets, Current USD 147.85M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap AssetsFairValueAdjustment Assets, Fair Value Adjustment USD 279.92M 2022-01-01 2022-12-31 2023 FY 10-K 2024-03-28 0000950170-24-037610
us-gaap AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value USD 0 2021-12-31 2022 Q2 10-Q 2022-08-15 0000950170-22-017242
us-gaap AvailableForSaleSecuritiesDebtSecurities Debt Securities, Available-for-sale USD 400,000 2022-12-31 8-K 2024-02-09 0000950170-24-013243
us-gaap BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized Business Combination, Separately Recognized Transactions, Expenses and Losses Recognized USD 7.50M 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-31 0000950170-22-005112
us-gaap CashAndCashEquivalentsAtCarryingValue Cash and Cash Equivalents, at Carrying Value USD 126.40M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents USD 127.41M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect USD -99.28M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Class of Warrant or Right, Exercise Price of Warrants or Rights USD/shares 3.48 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap ClassOfWarrantOrRightOutstanding Class of Warrant or Right, Outstanding shares 6.82M 2024-09-30 2024 Q3 10-Q 2024-11-14 0000950170-24-126735
us-gaap CommitmentsAndContingencies Commitments and Contingencies USD 0 2022-12-31 8-K 2024-02-09 0000950170-24-013243
us-gaap CommonStockCapitalSharesReservedForFutureIssuance Common Stock, Capital Shares Reserved for Future Issuance shares 36.89M 2021-12-31 2021 FY 10-K 2022-03-31 0000950170-22-005112
us-gaap CommonStockParOrStatedValuePerShare Common Stock, Par or Stated Value Per Share USD/shares 0 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap CommonStockSharesAuthorized Common Stock, Shares Authorized shares 1.00B 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap CommonStockSharesIssued Common Stock, Shares, Issued shares 295.63M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap CommonStockSharesOutstanding Common Stock, Shares, Outstanding shares 295.63M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap CommonStockValue Common Stock, Value, Issued USD 29,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap ComprehensiveIncomeNetOfTax Comprehensive Income (Loss), Net of Tax, Attributable to Parent USD -119.25M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap ConvertibleDebt Convertible Debt USD 1.00B 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092547
us-gaap ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue Convertible Preferred Stock, Nonredeemable or Redeemable, Issuer Option, Value USD 0 2021-12-31 2021 FY 10-K 2022-03-31 0000950170-22-005112
us-gaap ConvertiblePreferredStockSharesIssuedUponConversion Convertible Preferred Stock, Shares Issued upon Conversion shares 63.24M 2020-12-31 2021 FY 10-K 2022-03-31 0000950170-22-005112
us-gaap ConvertiblePreferredStockSharesReservedForFutureIssuance Convertible Preferred Stock, Shares Reserved for Future Issuance shares 59.07M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap CostOfGoodsAndServicesSoldDepreciationAndAmortization Cost, Depreciation and Amortization USD 538,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap CostsAndExpenses Costs and Expenses USD 167.11M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap CostsAndExpensesRelatedParty Costs and Expenses, Related Party USD 4.15M 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-31 0000950170-22-005112
us-gaap DebtInstrumentBasisSpreadOnVariableRate1 Debt Instrument, Basis Spread on Variable Rate pure 0.003 2025-04-18 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer USD 0 2022-06-30 2022 Q2 10-Q 2022-08-15 0000950170-22-017242
us-gaap DeferredIncomeTaxLiabilities Deferred Tax Liabilities, Gross USD 719,000 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092547
us-gaap DeferredOfferingCosts Deferred Offering Costs USD 0 2021-12-31 2021 FY 10-K 2022-03-31 0000950170-22-005112
us-gaap DeferredRevenue Deferred Revenue USD 1.68M 2024-06-30 2024 Q2 10-Q 2024-08-14 0000950170-24-096674
us-gaap DeferredTaxAssetsGoodwillAndIntangibleAssets Deferred Tax Assets, Goodwill and Intangible Assets USD 3.27M 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092547
us-gaap DeferredTaxAssetsGross Deferred Tax Assets, Gross USD 252.95M 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092547
us-gaap DeferredTaxAssetsInProcessResearchAndDevelopment Deferred Tax Assets, in Process Research and Development USD 30.93M 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092547
us-gaap DeferredTaxAssetsLiabilitiesNet Deferred Tax Assets, Net USD 0 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092547
us-gaap DeferredTaxAssetsNet Deferred Tax Assets, Net of Valuation Allowance USD 719,000 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092547
us-gaap DeferredTaxAssetsOperatingLossCarryforwards Deferred Tax Assets, Operating Loss Carryforwards USD 119.10M 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092547
us-gaap DeferredTaxAssetsOther Deferred Tax Assets, Other USD 1.50M 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092547
us-gaap DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost USD 18.87M 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092547
us-gaap DeferredTaxAssetsValuationAllowance Deferred Tax Assets, Valuation Allowance USD 252.23M 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092547
us-gaap DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs USD 74.35M 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092547
us-gaap Depreciation Depreciation USD 382,000 2024-01-01 2024-09-30 2024 Q3 10-Q 2024-11-14 0000950170-24-126735
us-gaap EarningsPerShareBasic Earnings Per Share, Basic USD/shares -0.38 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap EarningsPerShareBasicAndDiluted Earnings Per Share, Basic and Diluted USD/shares -0.93 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-13 0000950170-22-009799
us-gaap EarningsPerShareDiluted Earnings Per Share, Diluted USD/shares -0.38 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092547
us-gaap EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent pure 0.21 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092547
us-gaap EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent pure -0.224 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092547
us-gaap EffectiveIncomeTaxRateReconciliationCrossBorderOtherAmount EffectiveIncomeTaxRateReconciliationCrossBorderOtherAmount USD 25,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092547
us-gaap EffectiveIncomeTaxRateReconciliationCrossBorderOtherPercent EffectiveIncomeTaxRateReconciliationCrossBorderOtherPercent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092547
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent pure -0.005 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092547
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent pure 0 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-31 0000950170-22-005112
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent pure -0.013 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092547
us-gaap EffectiveIncomeTaxRateReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Percent pure -0.002 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092547
us-gaap EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent pure -0.033 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092547
us-gaap EffectiveIncomeTaxRateReconciliationTaxCredits Effective Income Tax Rate Reconciliation, Tax Credit, Percent pure -0.034 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092547
us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount USD 21.70M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount USD 12.70M 2025-09-30 2025 Q3 10-Q 2025-11-06 0001193125-25-268076
us-gaap FairValueAdjustmentOfWarrants Fair Value Adjustment of Warrants USD 0 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-28 0000950170-24-037610
us-gaap GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments Gain (Loss) on Investments, Excluding Other than Temporary Impairments USD 0 2021-01-01 2021-09-30 2021 Q3 10-Q 2021-11-15 0000950170-21-004586
us-gaap ImpairmentOfLongLivedAssetsHeldForUse Impairment of Long-Lived Assets Held-for-use USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092547
us-gaap IncomeLossFromContinuingOperationsPerBasicAndDilutedShare Income (Loss) from Continuing Operations, Per Basic and Diluted Share USD/shares -0.93 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-13 0000950170-22-009799
us-gaap IncomeTaxExpenseBenefit Income Tax Expense (Benefit) USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount USD 11.75M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092547
us-gaap IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount USD -11.02M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092547
us-gaap IncomeTaxReconciliationNondeductibleExpenseOther Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount USD 283,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092547
us-gaap IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount USD 682,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092547
us-gaap IncomeTaxReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Amount USD 77,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092547
us-gaap IncomeTaxReconciliationTaxCredits Effective Income Tax Rate Reconciliation, Tax Credit, Amount USD 1.80M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092547
us-gaap IncreaseDecreaseInAccountsPayable Increase (Decrease) in Accounts Payable USD -7.28M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap IncreaseDecreaseInAccountsReceivable Increase (Decrease) in Accounts Receivable USD -1.73M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap IncreaseDecreaseInAccruedLiabilities Increase (Decrease) in Accrued Liabilities USD 10,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap IncreaseDecreaseInContractWithCustomerLiability Increase (Decrease) in Contract with Customer, Liability USD 0 2025-01-01 2025-06-30 2025 Q2 10-Q 2025-08-14 0000950170-25-109029
us-gaap IncreaseDecreaseInDeferredRevenue Increase (Decrease) in Deferred Revenue USD 1.68M 2024-01-01 2024-06-30 2024 Q2 10-Q 2024-08-14 0000950170-24-096674
us-gaap IncreaseDecreaseInInventories Increase (Decrease) in Inventories USD -159,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap IncreaseDecreaseInOperatingLeaseLiability IncreaseDecreaseInOperatingLeaseLiability USD -707,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap IncreaseDecreaseInOtherCurrentLiabilities Increase (Decrease) in Other Current Liabilities USD 39,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap IncreaseDecreaseInOtherNoncurrentAssets Increase (Decrease) in Other Noncurrent Assets USD 97,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap IncreaseDecreaseInOtherNoncurrentLiabilities Increase (Decrease) in Other Noncurrent Liabilities USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092547
us-gaap IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Increase (Decrease) in Prepaid Expense and Other Assets USD 1.55M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap InterestIncomeExpenseNonoperatingNet Interest Income (Expense), Nonoperating, Net USD 4.47M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap InterestReceivable Interest Receivable USD 682,000 2021-09-30 2021 Q3 10-Q 2021-11-15 0000950170-21-004586
us-gaap InterestReceivableCurrent Interest Receivable, Current USD 375,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap InventoryFinishedGoods Inventory, Finished Goods, Gross USD 4.46M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap InventoryNet Inventory, Net USD 25.39M 2025-09-30 2025 Q3 10-Q 2025-11-06 0001193125-25-268076
us-gaap InventoryNoncurrent Inventory, Noncurrent USD 25.23M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap InventoryWorkInProcess Inventory, Work in Process, Gross USD 20.77M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap InvestmentIncomeInterest Investment Income, Interest USD 80,000 2021-01-01 2021-09-30 2021 Q3 10-Q 2021-11-15 0000950170-21-004586
us-gaap LeaseCost Lease, Cost USD 1.67M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap LesseeOperatingLeaseLiabilityPaymentsDue Lessee, Operating Lease, Liability, to be Paid USD 1.69M 2022-09-30 2022 Q3 10-Q 2022-11-10 0000950170-22-024516
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Lessee, Operating Lease, Liability, to be Paid, Year One USD 411,000 2022-09-30 2022 Q3 10-Q 2022-11-10 0000950170-22-024516
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFour Lessee, Operating Lease, Liability, to be Paid, Year Four USD 328,000 2022-09-30 2022 Q3 10-Q 2022-11-10 0000950170-22-024516
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearThree Lessee, Operating Lease, Liability, to be Paid, Year Three USD 430,000 2022-09-30 2022 Q3 10-Q 2022-11-10 0000950170-22-024516
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Lessee, Operating Lease, Liability, to be Paid, Year Two USD 421,000 2022-09-30 2022 Q3 10-Q 2022-11-10 0000950170-22-024516
us-gaap LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year USD 102,000 2022-09-30 2022 Q3 10-Q 2022-11-10 0000950170-22-024516
us-gaap LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths Lessor, Operating Lease, Payment to be Received, Year One USD 1.40M 2023-12-31 2023 FY 10-K 2024-03-28 0000950170-24-037610
us-gaap Liabilities Liabilities USD 33.42M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap LiabilitiesAndStockholdersEquity Liabilities and Equity USD 183.91M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap LiabilitiesCurrent Liabilities, Current USD 26.81M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap LineOfCreditFacilityCommitmentFeeAmount Line of Credit Facility, Commitment Fee Amount USD 30.00M 2025-04-18 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap MarketableSecurities Marketable Securities USD 0 2023-12-31 2023 FY 10-K 2024-03-28 0000950170-24-037610
us-gaap MarketableSecuritiesGainLoss Marketable Securities, Gain (Loss) USD 0 2022-01-01 2022-12-31 8-K 2024-02-09 0000950170-24-013243
us-gaap MarketableSecuritiesRealizedGainLoss Marketable Securities, Realized Gain (Loss) USD 0 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-28 0000950170-24-037610
us-gaap NetCashProvidedByUsedInFinancingActivities Net Cash Provided by (Used in) Financing Activities USD 19.37M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap NetCashProvidedByUsedInInvestingActivities Net Cash Provided by (Used in) Investing Activities USD -1.82M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap NetCashProvidedByUsedInOperatingActivities Net Cash Provided by (Used in) Operating Activities USD -116.83M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap NetIncomeLoss Net Income (Loss) Attributable to Parent USD -119.26M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap NonoperatingIncomeExpense Nonoperating Income (Expense) USD 4.37M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap NumberOfReportableSegments Number of Reportable Segments Segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap OperatingExpenses Operating Expenses USD 167.11M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap OperatingIncomeLoss Operating Income (Loss) USD -123.64M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap OperatingLeaseCost Operating Lease, Cost USD 1.67M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap OperatingLeaseLiability Operating Lease, Liability USD 376,000 2026-03-31 2026 Q1 10-Q 2026-05-14 0001193125-26-222779
us-gaap OperatingLeaseLiabilityCurrent Operating Lease, Liability, Current USD 1.64M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap OperatingLeaseLiabilityNoncurrent Operating Lease, Liability, Noncurrent USD 6.61M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap OperatingLeasePayments Operating Lease, Payments USD 1.12M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap OperatingLeaseRightOfUseAsset Operating Lease, Right-of-Use Asset USD 7.64M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap OperatingLeaseRightOfUseAssetAmortizationExpense Operating Lease, Right-of-Use Asset, Amortization Expense USD 1.26M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap OperatingLeasesFutureMinimumPaymentsDue Operating Leases, Future Minimum Payments Due USD 107.80M 2022-12-31 8-K 2024-02-09 0000950170-24-013243
us-gaap OperatingLeasesRentExpenseNet Operating Leases, Rent Expense, Net USD 1.30M 2022-01-01 2022-09-30 2022 Q3 10-Q 2022-11-10 0000950170-22-024516
us-gaap OtherAccruedLiabilitiesCurrentAndNoncurrent Other Accrued Liabilities USD 3.78M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap OtherAssetsCurrent Other Assets, Current USD 2.37M 2025-06-30 2025 Q2 10-Q 2025-08-14 0000950170-25-109029
us-gaap OtherAssetsNoncurrent Other Assets, Noncurrent USD 707,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent USD 6,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap OtherDeferredCompensationArrangementsLiabilityCurrentAndNoncurrent Other Deferred Compensation Arrangements, Liability, Current and Noncurrent USD 0 2022-01-01 2022 Q3 10-Q 2022-11-10 0000950170-22-024516
us-gaap OtherLiabilitiesCurrent Other Liabilities, Current USD 91,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap OtherLiabilitiesNoncurrent Other Liabilities, Noncurrent USD 0 2024-12-31 2024 FY 10-K 2025-03-20 0000950170-25-042332
us-gaap OtherNoncashIncomeExpense Other Noncash Income (Expense) USD -6,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap OtherNonoperatingGainsLosses Other Nonoperating Gains (Losses) USD 4.37M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap OtherResearchAndDevelopmentExpense Other Research and Development Expense USD 2.20M 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-20 0000950170-25-042332
us-gaap PartnersCapitalAccountPublicSaleOfUnitsNetOfOfferingCosts Partners' Capital Account, Public Sale of Units Net of Offering Costs USD 400.00M 2022-09-30 2025 Q3 10-Q 2025-11-06 0001193125-25-268076
us-gaap PaymentsForRepurchaseOfCommonStock Payments for Repurchase of Common Stock USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-20 0000950170-25-042332
us-gaap PaymentsForRepurchaseOfInitialPublicOffering Payments for Repurchase of Initial Public Offering USD 231,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap PaymentsToAcquireMarketableSecurities Payments to Acquire Marketable Securities USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-20 0000950170-25-042332
us-gaap PaymentsToAcquirePropertyPlantAndEquipment Payments to Acquire Property, Plant, and Equipment USD 1.82M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap PreferredStockLiquidationPreferenceValue Preferred Stock, Liquidation Preference, Value USD 505.40M 2021-06-30 2021 Q2 10-Q 2021-09-20 0000950170-21-001832
us-gaap PreferredStockParOrStatedValuePerShare Preferred Stock, Par or Stated Value Per Share USD/shares 0 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap PreferredStockSharesAuthorized Preferred Stock, Shares Authorized shares 10.00M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap PreferredStockSharesIssued Preferred Stock, Shares Issued shares 0 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap PreferredStockSharesOutstanding Preferred Stock, Shares Outstanding shares 0 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap PreferredStockValue Preferred Stock, Value, Issued USD 0 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap PrepaidExpenseAndOtherAssetsCurrent Prepaid Expense and Other Assets, Current USD 9.25M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap PrepaidExpenseAndOtherAssetsNoncurrent Prepaid Expense and Other Assets, Noncurrent USD 500,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap PrepaidInsurance Prepaid Insurance USD 343,000 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-349215
us-gaap ProceedsFromIssuanceInitialPublicOffering Proceeds from Issuance Initial Public Offering USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap ProceedsFromIssuanceOfCommonStock Proceeds from Issuance of Common Stock USD 364,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap ProceedsFromIssuanceOfConvertiblePreferredStock Proceeds from Issuance of Convertible Preferred Stock USD 0 2022-01-01 2022-12-31 8-K 2024-02-09 0000950170-24-013243
us-gaap ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock Proceeds from Issuance of Redeemable Convertible Preferred Stock USD 0 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-31 0000950170-22-005112
us-gaap ProceedsFromIssuanceOfWarrants Proceeds from Issuance of Warrants USD 17.37M 2022-01-01 2022-12-31 2023 FY 10-K 2024-03-28 0000950170-24-037610
us-gaap ProceedsFromLicenseFeesReceived Proceeds from License Fees Received USD 200,000 2023-06-01 2023-06-30 2023 Q3 10-Q 2023-11-09 0000950170-23-062043
us-gaap ProceedsFromSaleAndMaturityOfMarketableSecurities Proceeds from Sale and Maturity of Marketable Securities USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-20 0000950170-25-042332
us-gaap ProceedsFromStockOptionsExercised Proceeds from Stock Options Exercised USD 115,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap ProfitLoss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest USD -119.26M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap PropertyPlantAndEquipmentNet Property, Plant and Equipment, Net USD 2.48M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap PurchaseObligation Purchase Obligation USD 12.73M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap PurchaseObligationDueAfterFifthYear Purchase Obligation, to be Paid, after Year Five USD 6.54M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap PurchaseObligationDueInFifthYear Purchase Obligation, to be Paid, Year Five USD 1.05M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap PurchaseObligationDueInFourthYear Purchase Obligation, to be Paid, Year Four USD 1.03M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap PurchaseObligationDueInNextTwelveMonths Purchase Obligation, to be Paid, Year One USD 638,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap PurchaseObligationDueInSecondYear Purchase Obligation, to be Paid, Year Two USD 2.55M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap PurchaseObligationDueInThirdYear Purchase Obligation, to be Paid, Year Three USD 919,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear Purchase Obligation, to be Paid, Remainder of Fiscal Year USD 435,000 2023-09-30 2023 Q3 10-Q 2023-11-09 0000950170-23-062043
us-gaap RealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments Realized Gain (Loss) on Marketable Securities, Cost Method Investments, and Other Investments USD 0 2021-01-01 2021-09-30 2021 Q3 10-Q 2021-11-15 0000950170-21-004586
us-gaap RealizedInvestmentGainsLosses Realized Investment Gains (Losses) USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-20 0000950170-25-042332
us-gaap ResearchAndDevelopmentExpense Research and Development Expense USD 78.83M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap ResearchAndDevelopmentInProcess Research and Development in Process USD 0 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-31 0000950170-22-005112
us-gaap RestrictedCash Restricted Cash USD 511,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap RestrictedCashCurrent Restricted Cash, Current USD 511,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap RestrictedCashEquivalents Restricted Cash Equivalents USD 1.01M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap RetainedEarningsAccumulatedDeficit Retained Earnings (Accumulated Deficit) USD -1.07B 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap Revenues Revenues USD 43.48M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability Right-of-Use Asset Obtained in Exchange for Finance Lease Liability USD 0 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-28 0000950170-24-037610
us-gaap RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability USD 0 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-28 0000950170-24-037610
us-gaap RoyaltyExpense Royalty Expense USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap SaleLeasebackTransactionMonthlyRentalPayments Sale Leaseback Transaction, Monthly Rental Payments USD 1.30M 2022-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-349215
us-gaap SaleOfStockPricePerShare Sale of Stock, Price Per Share USD/shares 8 2022-09-30 2022 Q3 10-Q 2022-11-10 0000950170-22-024516
us-gaap SellingGeneralAndAdministrativeExpense Selling, General and Administrative Expense USD 84.93M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap ShareBasedCompensation Share-based Payment Arrangement, Noncash Expense USD 8.33M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding USD 300,000 2022-03-31 2022 Q1 10-Q 2022-05-13 0000950170-22-009799
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period shares 100,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value USD/shares 1.15 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period shares 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value USD/shares 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number shares 0 2023-12-31 2023 FY 10-K 2024-03-28 0000950170-24-037610
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period shares 1.34M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value USD/shares 1.54 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised shares 124,578 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized shares 2.69M 2021-07-31 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value USD 114,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number shares 14.42M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price USD/shares 3.57 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value USD 100,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period shares 3.40M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross shares 24.02M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value USD/shares 0.83 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value USD 690,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number shares 41.85M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price USD/shares 2.08 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value USD 690,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number shares 41.85M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price USD/shares 2.08 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price USD/shares 0.92 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price USD/shares 1.96 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price USD/shares 1.28 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants USD 11.10M 2025-07-01 2025-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap StockholdersEquity Stockholders' Equity Attributable to Parent USD 150.48M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap StockIssuedDuringPeriodSharesNewIssues Stock Issued During Period, Shares, New Issues shares 700,000 2022-01-01 2022-12-31 8-K 2024-02-09 0000950170-24-013243
us-gaap StockIssuedDuringPeriodSharesStockOptionsExercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period shares 172,223 2024-04-01 2024-06-30 2025 Q3 10-Q 2025-11-06 0001193125-25-268076
us-gaap StockIssuedDuringPeriodValueConversionOfConvertibleSecurities Stock Issued During Period, Value, Conversion of Convertible Securities USD 504.71M 2021-01-01 2021-12-31 8-K 2024-02-09 0000950170-24-013243
us-gaap StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Stock Issued During Period, Value, Employee Stock Purchase Plan USD 109,000 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap StockIssuedDuringPeriodValueNewIssues Stock Issued During Period, Value, New Issues USD 39.06M 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092547
us-gaap StockIssuedDuringPeriodValueStockOptionsExercised Stock Issued During Period, Value, Stock Options Exercised USD 2,000 2023-01-01 2023-12-31 2024 FY 10-K 2025-03-20 0000950170-25-042332
us-gaap StockRepurchasedAndRetiredDuringPeriodShares Stock Repurchased and Retired During Period, Shares shares 468,751 2021-11-01 2021-11-30 2021 FY 10-K 2022-03-31 0000950170-22-005112
us-gaap StockRepurchasedDuringPeriodShares Stock Repurchased During Period, Shares shares 5.00M 2022-01-01 2022-09-30 2022 Q3 10-Q 2022-11-10 0000950170-22-024516
us-gaap StockRepurchasedDuringPeriodValue Stock Repurchased During Period, Value USD 40.00M 2022-01-01 2022-09-30 2022 Q3 10-Q 2022-11-10 0000950170-22-024516
us-gaap SubordinatedBorrowingInterestRate Subordinated Borrowing, Interest Rate pure 0.079 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap TemporaryEquityLiquidationPreference Temporary Equity, Liquidation Preference USD 169.90M 2020-12-31 2021 FY 10-K 2022-03-31 0000950170-22-005112
us-gaap TemporaryEquitySharesAuthorized Temporary Equity, Shares Authorized shares 12.65M 2020-12-31 2021 FY 10-K 2022-03-31 0000950170-22-005112
us-gaap TemporaryEquitySharesIssued Temporary Equity, Shares Issued shares 12.65M 2020-12-31 2021 FY 10-K 2022-03-31 0000950170-22-005112
us-gaap TemporaryEquitySharesOutstanding Temporary Equity, Shares Outstanding shares 12.65M 2020-12-31 2021 FY 10-K 2022-03-31 0000950170-22-005112
us-gaap TreasuryStockCommonShares Treasury Stock, Common, Shares shares 0 2022-12-31 8-K 2024-02-09 0000950170-24-013243
us-gaap TreasuryStockShares Treasury Stock, Shares shares 0 2022-12-31 2022 FY 10-K 2023-03-23 0000950170-23-009516
us-gaap TreasuryStockSharesRetired Treasury Stock, Shares, Retired shares 2.62M 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-23 0000950170-23-009516
us-gaap TreasuryStockValue Treasury Stock, Value USD 0 2022-12-31 8-K 2024-02-09 0000950170-24-013243
us-gaap UnrealizedGainOnSecurities Unrealized Gain on Securities USD 3,000 2021-01-01 2021-09-30 2021 Q3 10-Q 2021-11-15 0000950170-21-004586
us-gaap UnrealizedLossOnSecurities Unrealized Loss on Securities USD 0 2021-01-01 2021-09-30 2021 Q3 10-Q 2021-11-15 0000950170-21-004586
us-gaap UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued USD 0 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092547
us-gaap ValuationAllowanceDeferredTaxAssetChangeInAmount Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount USD 7.78M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-092547
us-gaap VariableLeaseCost Variable Lease, Cost USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap WeightedAverageNumberOfDilutedSharesOutstanding Weighted Average Number of Shares Outstanding, Diluted shares 317.56M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034
us-gaap WeightedAverageNumberOfShareOutstandingBasicAndDiluted Weighted Average Number of Shares Outstanding, Basic and Diluted shares 107.87M 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-13 0000950170-22-009799
us-gaap WeightedAverageNumberOfSharesOutstandingBasic Weighted Average Number of Shares Outstanding, Basic shares 317.56M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462034

Financialist News Desk

Our desk turns official SEC filings into news. Each story is checked against the original filing. About us → · Editorial standards →